Enfusion Operating Income from 2010 to 2024
| ENFN Stock | USD 9.00 0.09 1.01% |
Operating Income | First Reported 2010-12-31 | Previous Quarter 11.9 M | Current Value 12.5 M | Quarterly Volatility 74.4 M |
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 5 M, as well as many indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
Enfusion | Operating Income |
Latest Enfusion's Operating Income Growth Pattern
Below is the plot of the Operating Income of Enfusion over the last few years. Operating Income is the amount of profit realized from Enfusion operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Enfusion is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Enfusion's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Enfusion Operating Income Regression Statistics
| Arithmetic Mean | (7,906,040) | |
| Geometric Mean | 15,603,449 | |
| Coefficient Of Variation | (941.56) | |
| Mean Deviation | 36,271,456 | |
| Median | 13,869,000 | |
| Standard Deviation | 74,439,843 | |
| Sample Variance | 5541.3T | |
| Range | 289.8M | |
| R-Value | (0.29) | |
| Mean Square Error | 5479.9T | |
| R-Squared | 0.08 | |
| Significance | 0.30 | |
| Slope | (4,758,404) | |
| Total Sum of Squares | 77578.1T |
Enfusion Operating Income History
Other Fundumenentals of Enfusion
Enfusion Operating Income component correlations
Click cells to compare fundamentals
About Enfusion Financial Statements
Enfusion investors utilize fundamental indicators, such as Operating Income, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 11.9 M | 12.5 M | |
| Non Operating Income Net Other | -574.2 K | -602.9 K |
Pair Trading with Enfusion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Enfusion Stock
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:Check out the analysis of Enfusion Correlation against competitors. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.572 | Earnings Share 0.04 | Revenue Per Share 2.11 | Quarterly Revenue Growth 0.158 | Return On Assets 0.0374 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.